Selumetinib - AstraZeneca

Drug Profile

Selumetinib - AstraZeneca

Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; MK 5618; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; Samsung Medical Center; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Neurofibromatoses; Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thyroid cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Astrocytoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 10 Jul 2018 M.D. Anderson Cancer Center plans a phase I/II trial for Non small Cell Lung Cancer (Late-stage disease; Second-line therapy or greater) in USA , (NCT03581487)
  • 01 Jun 2018 Efficacy and adverse events data from a phase II trial in Gastric cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Efficacy and adverse events data from a phase II trial in Biliary tract cancer (BTC) (Late-stage disease, Combination therapy) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO- 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top